BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 16417592)

  • 1. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc.
    Dressler D; Hallett M
    Eur J Neurol; 2006 Feb; 13 Suppl 1():11-5. PubMed ID: 16417592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin drugs: brief history and outlook.
    Dressler D
    J Neural Transm (Vienna); 2016 Mar; 123(3):277-9. PubMed ID: 26559824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.
    Dressler D; Bigalke H
    J Neurol; 2005 Aug; 252(8):904-7. PubMed ID: 15761672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of therapeutic botulinum toxin preparations.
    Dressler D; Benecke R
    Disabil Rehabil; 2007 Dec; 29(23):1761-8. PubMed ID: 18033601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological aspects of therapeutic botulinum toxin preparations].
    Dressler D
    Nervenarzt; 2006 Aug; 77(8):912-21. PubMed ID: 16810528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical use of non-A botulinum toxins: botulinum toxin type B.
    Dressler D; Eleopra R
    Neurotox Res; 2006 Apr; 9(2-3):121-5. PubMed ID: 16785108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin for treatment of dystonia.
    Dressler D
    Eur J Neurol; 2010 Jul; 17 Suppl 1():88-96. PubMed ID: 20590814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-induced failure of botulinum toxin type B therapy in de novo patients.
    Dressler D; Bigalke H
    Eur Neurol; 2004; 52(3):132-5. PubMed ID: 15479980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.
    Bhidayasiri R; Cardoso F; Truong DD
    Eur J Neurol; 2006 Feb; 13 Suppl 1():21-9. PubMed ID: 16417594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences.
    Barnes MP; Best D; Kidd L; Roberts B; Stark S; Weeks P; Whitaker J
    Eur J Neurol; 2005 Dec; 12(12):947-55. PubMed ID: 16324088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin therapy for cervical dystonia.
    Jankovic J
    Neurotox Res; 2006 Apr; 9(2-3):145-8. PubMed ID: 16785112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin (Botox, Dysport, and Myobloc): pharmacology 101.
    Wynn RL
    Gen Dent; 2011; 59(2):88-90. PubMed ID: 21903516
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunological aspects of botulinum toxin therapy.
    Dressler D; Bigalke H
    Expert Rev Neurother; 2017 May; 17(5):487-494. PubMed ID: 27852103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year experience with incobotulinumtoxinA (Xeomin(®) ): the first botulinum toxin drug free of complexing proteins.
    Dressler D
    Eur J Neurol; 2012 Mar; 19(3):385-9. PubMed ID: 22035051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin therapy of hemifacial spasm: comparing different therapeutic preparations.
    Frei K; Truong DD; Dressler D
    Eur J Neurol; 2006 Feb; 13 Suppl 1():30-5. PubMed ID: 16417595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse diaphragm assay for detection of antibodies against botulinum toxin type B.
    Dressler D; Lange M; Bigalke H
    Mov Disord; 2005 Dec; 20(12):1617-9. PubMed ID: 16078216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.
    Dressler D
    Mov Disord; 2004 Mar; 19 Suppl 8():S92-S100. PubMed ID: 15027060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of botulinum toxin: differences between type A preparations.
    Rosales RL; Bigalke H; Dressler D
    Eur J Neurol; 2006 Feb; 13 Suppl 1():2-10. PubMed ID: 16417591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Different botulinum toxins and their specifications].
    Beylot C
    Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S77-85. PubMed ID: 19576490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.